Evidence map›Paper›PMID 34071798›Full record

ArticleFoods (Basel, Switzerland)2021

Yeast Particle Encapsulation of Scaffolded Terpene Compounds for Controlled Terpene Release.

Ernesto R Soto, Florentina Rus, Hanchen Li, Carli Garceau, Jeffrey Chicca, Mostafa Elfawal, David Gazzola, Martin K Nielsen, Joseph F Urban, Raffi V Aroian and 1 more

Open access · goldAbstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ernesto R SotoProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.ORCID 0000-0002-9540-8476
Florentina RusProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Hanchen LiProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Carli GarceauProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Jeffrey ChiccaProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Mostafa ElfawalProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
David GazzolaProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Martin K NielsenM.H. Gluck Equine Research Center, Department of Veterinary Science, University of Kentucky, Lexington, KY 40546, USA.
Joseph F UrbanBeltsville Human Nutrition Research Center, Diet, Genomics and Immunology Laboratory, United States Department of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA.ORCID 0000-0002-1590-8869
Raffi V AroianProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
Gary R OstroffProgram in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.
University of Massachusetts Chan Medical School · USAgricultural Research Service · USUniversity of Kentucky · US

Funding

Function/optimization of a nematicidal Cry toxin arsenalR01AI056189 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI RAFFI V AROIAN · 2005 to 2026
$11.0M
Automated high throughput compound screening for broadly active anti-parasitic nematode drugsR01AI150866 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI AROIAN, RAFFI V · 2020 to 2024
$2.5M
Eden Research plc Sponsored Research AgreementNIAID NIH HHS R01 AI056189NIAID NIH HHS R01 AI150866NIH HHS R01AI056189 and R01AI50866U.S. Department of Agriculture 2015-11323
6 · The paper itself

Abstract

Terpenes are naturally occurring compounds produced by plants that are of great commercial interest in the food, agricultural, cosmetic, and pharmaceutical industries due to their broad spectra of antibacterial, antifungal, anthelmintic, membrane permeation enhancement, and antioxidant biological activities. Applications of terpenes are often limited by their volatility and the need for surfactants or alcohols to produce stable, soluble (non-precipitated) products. Yeast particles (YPs) are hollow, porous microspheres that have been used for the encapsulation of terpenes (YP terpenes) by passive diffusion of terpenes through the porous YP cell walls. We here report the development of a second generation YP encapsulated terpene technology that incorporates the stimuli-responsive control of terpene release using biodegradable pro-terpene compounds (YP pro-terpenes). YP terpenes and YP pro-terpenes were both produced, in which high levels of carvacrol, eugenol, thymol and geraniol were encapsulated. The YP pro-terpenes show higher encapsulation stability than YP terpenes due to pro-terpenes being non-volatile solids at room temperature and stable in suspensions at neutral pH. YP pro-terpenes and YP terpenes were evaluated for biological activity in antibacterial, antifungal and anthelmintic assays. The YP pro-terpenes retained the full biological activity of the parent terpene compound.

Indexed as

anthelminticantimicrobialprodrugterpenesyeast particles

Identifiers

PMID34071798
PMCPMC8228553
OpenAlexW3164226313

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.